Explore our news

18.07.2022

STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

The European Commission (EC) has granted conditional marketing authorization for Kinpeygo^®

08.07.2022

STADA Health Report 2022: Europe experiencing worsening health conditions

Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…

25.06.2022

People with Parkinson’s are missing out on regular specialist advice in much of Europe

Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …

09.06.2022

STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market

20.05.2022

STADA set to expand Specialty portfolio with positive CHMP opinion on Kinpeygo orphan medicine for IgAN kidney disease

STADA has taken a significant step towards expanding its Specialty portfolio

22.04.2022

STADA brings in Berndt to further develop specialties and biosimilars offerings

Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars

06.04.2022

Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)

A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

22.03.2022

STADA’s 2021 above-market development strengthens base for further growth, especially in Consumer Healthcare and Specialty

Full-year results 2021

18.03.2022

Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China

Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong…

19.01.2022

STADA expands production network with EUR50m project in Romania

STADA is preparing to meet demand for its expanding portfolio by investing almost EUR50 million in a supply-chain hub in Turda, Romania

05.01.2022

STADA sets up for success with Erin Federman as global biosimilars commercial head

Experienced expert Erin Federman will oversee commercialization of STADA’s biosimilars portfolio and pipeline

26.08.2021

STADA continues to outpace the market in H1 and strengthens basis for further growth

Half-year results 2021

27.07.2021

STADA and Sanofi strike consumer healthcare distribution agreement in selected countries in Europe

21.07.2021

Calliditas Therapeutics and STADA

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

12.07.2021

Enzymatica and STADA extend agreement on ViruProtect to Vietnam

Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect^® (distributed by Enzymatica as ColdZyme^®) in Vietnam.

29.06.2021

STADA and partner Xbrane advance biosimilar ranibizumab candidate

28.06.2021

STADA further grows European Consumer Healthcare portfolio by acquiring 16 well-established brands from Sanofi

17.06.2021

STADA Health Report 2021

A year that changed Europe’s health landscape

31.03.2021

STADA focuses even more on a future-oriented growth culture Head of Global Human Resources Simone Berger moves up to STADA's Executive Board

30.03.2021

STADA strengthens oncology offering by launching bevacizumab biosimilar

All Press Releases

STADA Health Report 2022

Is Europe on the brink of a health collapse? Europe, early summer 2021: Covid vaccination programmes across Europe were in full flow, bringing the prospect of returning to life more like we knew it before the pandemic. But had the virus changed the way we lived irreversibly? By asking detailed questions of 30,000 people across 15 countries, the STADA Health Report 2021 brought to light the immediate short-term effects of the pandemic on the lives of Europeans.

One year later, STADA checked in with Europeans to learn what longer-term effects the pandemic has left on Europe’s health landscape: How is their mental health holding up? What is worrying them? All the answers can be found in the STADA Health Report 2022

STADA Image Film 2022

What drives the company? STADA promotes its purpose with an emotional film stating, that health is at the heart of the company's everyday work. The video spotlights how each and every employee is aiming to improve people’s lives every day.

“Caring for People’s Health as a Trusted Partner” is STADA’s purpose and guides as a north star. The purpose is the foundation of all companies’ actions and unites all employees globally as a team. One STADA team with the aim: bringing health to society.

Generics and Specialties

One of STADA's important business areas is the production and sales of inexpensive medicines that are generally known as generics. This area also includes specialties like biosimilars.

Digital health knowledge

We are convinced that if you want to stay healthy, you cannot do without one thing: Health knowledge. Because of this, we have set ourselves the goal of raising awareness of health issues. Our blog section "Stories" offers helpful information and tips.

STADA Stories

Consumer Healthcare products

Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Consumer Healthcare brands such as Zoflora®, Grippostad®, Snup®, Aqualor®, Vitaprost® and Nizoral® are among the top sellers in their respective product categories.